Loading...

SNGX SOLIGENIX INC Expansion Plans 8-K Filing

SLGN

SNGX

SOLIGENIX INC

(SNGX)

2025 8-K

Compliance Regained

Funding Announcement

FDA Grants Designation

Nasdaq Non-Compliance

Product Expansion

Bylaw Amendment

Loan Termination

Stock Sale Agreement

Warrant Inducement Agreement

Reverse Stock Split

Annual Meeting Adjournment

Compliance with NASDAQ Requ...

Delisting Notice

Annual Meeting of Stockholders

Meeting Adjournment

Annual Meeting Adjournment

Adjournment of Annual Meeti...

Accounting Firm Change

Securities Purchase Agreeme...

Director Compensation Polic...

Investment Agreement

Loan Agreement Amendment

External Links:

On July 31, 2025, Soligenix, Inc. announced that it successfully completed its Phase 2a proof of concept study for SGX945 in treating Behçet's Disease, achieving the objective of demonstrating biological efficacy.

AI Assistant

SOLIGENIX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.